What is Mazdutide? Benefits, Risks & Comparisons

Mazdutide research peptide vial with dosage and benefit information

“What is Mazdutide?” usually means you want a straight answer—what it is, what it does, and whether it’s genuinely different from the GLP‑1 drugs you already know. You may also see “GLP1” written online; the standard scientific form is GLP‑1 (with a hyphen), and we’ll use that consistently.

This guide explains Mazdutide’s mechanism, the strongest human trial results, the most common side effects, and how it compares to popular GLP‑1 and dual‑incretin options—without hype or medical claims. [1]

Educational content only. Not medical advice, diagnosis, or treatment guidance. The goal is informed understanding.

Fast Answer / Executive Summary

Mazdutide is a once‑weekly dual‑agonist peptide that activates GLP‑1 and glucagon receptors to support weight loss and metabolic improvements. In a large 48‑week phase 3 trial in Chinese adults with overweight/obesity, Mazdutide produced about −11% to −14% average weight loss at week 48 (dose‑dependent), with gastrointestinal effects (nausea, diarrhea, vomiting) as the most common side effects. [2]

Core Concepts & Key Entities

What is Mazdutide?

Mazdutide is a synthetic peptide designed to mimic (and refine) a natural gut‑hormone signaling pattern to help with body‑weight reduction and metabolic risk factors. In the key obesity trial (GLORY‑1), it was administered as a once‑weekly subcutaneous injection with a dose‑escalation period before maintenance dosing. [3]

A simple way to define it for featured‑snippet clarity:

Mazdutide is a dual receptor agonist that targets GLP‑1 receptor (GLP‑1R) and glucagon receptor (GCGR). [4]

Which receptors does Mazdutide target—and why does that matter?

Mazdutide activates two receptors:

GLP‑1 receptor (GLP‑1R)
Glucagon receptor (GCGR) [4]

That pairing matters because it’s meant to combine: – GLP‑1’s effects on satiety, appetite, and glycemic regulation, and – glucagon‑pathway effects that can influence energy balance and hepatic lipid metabolism (while recognizing glucagon signaling can be hyperglycemic if unopposed). [5]

Mazdutide’s pharmacology is often described as a long‑acting, acylated analogue created from the “oxyntomodulin idea” (a hormone that can engage both GLP‑1 and glucagon receptors). [6]

What is GLP‑1—and what does it do in the body?

GLP‑1 is a gut‑derived hormone released after food intake that helps regulate blood glucose and satiety. GLP‑1 signaling can contribute to appetite reduction and—depending on context—delays gastric emptying, influencing post‑meal glucose handling. [7]

For beginners, think of GLP‑1 as a “meal‑response signal” that can: – increase satiety (help you feel full sooner), – reduce appetite drive, and – affect gut motility and stomach emptying. [7]

Where do “incretin,” insulin, and GIP fit in?

Incretins are gut hormones that enhance insulin secretion in a glucose‑dependent way after eating. In humans, the two classic incretins are GLP‑1 and GIP (glucose‑dependent insulinotropic polypeptide). [8]

One useful contrast: GLP‑1 receptor agonists are known to slow gastric emptying and reduce gut motility, while GIP does not have the same gastric‑emptying profile in the classic incretin literature. [9]

Why add glucagon receptor agonism at all?

Glucagon stimulates hepatic glucose production but is also linked to lipolysis and fatty acid oxidation—so researchers have explored glucagon agonism as a weight‑loss lever if its hyperglycemic effect can be counterbalanced. That concept is explicitly discussed in the GLORY‑1 trial write‑up. [10]

This is the “design bet” behind GLP‑1/glucagon dual agonists: – GLP‑1 helps with appetite, satiety, and glycemic control. – Glucagon‑pathway agonism may add metabolic “output” effects (energy expenditure / liver lipid handling), but needs balance. [5]

What are Mazdutide’s other names?

Mazdutide is also known as: – IBI362 – LY3305677 [11]

If you see those codes on forums or in older trial discussions, they refer to the same molecule family.

Is Mazdutide approved—and where?

Mazdutide received first approval in China[12] for long‑term weight management (with diet and exercise) in June 2025, and it has also been positioned as an approved therapy in that market context. [13]

Under U.S. Food and Drug Administration[14], Mazdutide is not presented as an FDA‑approved chronic weight‑management drug in the same way that semaglutide (Wegovy) and tirzepatide (Zepbound) are. [15]

Step‑by‑Step / How‑To

Step one: Verify what Mazdutide actually is (mechanism first)

Mazdutide is GLP‑1R + GCGR, not GLP‑1‑only and not GLP‑1/GIP. If you mix these up, every comparison you make afterward becomes misleading. [4]

Practical shortcut: if someone calls Mazdutide “like tirzepatide,” ask which second receptor they mean—GIP vs glucagon is a major fork in mechanism. [16]

Step two: Anchor your expectations to the best evidence (phase 3 > phase 2 > phase 1)

The highest‑weight evidence for weight loss is the phase 3 GLORY‑1 trial, which reports dose‑dependent average weight loss and detailed adverse‑event data over 48 weeks. [2]

Phase 2 evidence supports the same direction (dose‑response weight loss through 24 weeks), but phase 3 is the stronger anchor for “what happened at scale.” [17]

Step three: Read the trial endpoints like a pro (this is where most people get fooled)

Most people compare “percent weight loss” across drugs without checking: – time horizon (24 vs 48 vs 72 weeks), – population (with vs without diabetes; baseline BMI ranges), – and endpoint definition/analysis (how missing data and discontinuations are handled). [18]

Information‑gain framework: The Three‑Lens Trial Check 1. Time: What week is reported (48 vs 72)?
2. Population: With diabetes? Severe obesity only?
3. Treatment reality: Do results reflect “on‑treatment only,” or a broader policy/intent‑to‑treat approach?

GLORY‑1 reports outcomes at week 32 and week 48, and it includes weight regain during off‑treatment follow‑up—details that matter for real‑world expectations. [19]

Step four: Translate “percent loss” into something you can feel (without exaggerating)

Percent loss is easy to misread. Here’s a grounded translator:

If someone weighs 200 lb, then 10% ≈ 20 lb, 14% ≈ 28 lb.
That aligns with GLORY‑1’s ~11–14% average loss at week 48 (dose‑dependent). [20]

This is not a promise; it’s a way to interpret the scale of trial outcomes.

Step five: Check tolerability signals early (because that’s what drives discontinuation)

For GLP‑1‑based therapies, the most common limiting factor is tolerability—especially nausea, diarrhea, and vomiting, often clustered around dose escalation. GLORY‑1 reports GI events as the most frequent adverse events, generally mild‑to‑moderate, and discontinuation due to adverse events was low in that trial. [21]

If a page acts like side effects are optional or rare, that’s a credibility red flag.

Step six: Separate “secondary signals” from “proven outcomes”

GLORY‑1 reports improvements in cardiometabolic measures such as waist circumference and other markers, and it notes liver‑fat findings in participants with steatosis as a subgroup signal. [22]

That’s useful, but keep the hierarchy clear: – Primary outcomes (body‑weight change, responder rates) are strongest. – Secondary markers (lipids, blood pressure, uric acid, liver fat imaging) are supportive but can be misused for marketing if over‑interpreted. [23]

Comparison / Alternatives

How is Mazdutide different from popular “GLP‑1 era” options?

Mazdutide differs because it combines GLP‑1 receptor agonism with glucagon receptor agonism, while many mainstream options are GLP‑1‑only (semaglutide) or GLP‑1 + GIP (tirzepatide). [24]

That doesn’t automatically mean “better.” It means the mechanism and trade‑offs are different, and you should compare using matched evidence and timelines.

The most useful comparison table (mechanism + strongest trial‑style outcomes)

Option (category)	Main receptor targets	Typical trial timeframe referenced here	Average weight loss range (trial‑reported)	Common tolerability pattern	Best “fit” use‑case (informational)
Mazdutide (dual agonist)	GLP‑1R + GCGR	48 weeks	~−11% (4 mg) to ~−14% (6 mg) at week 48 in GLORY‑1; ≥15% responders ~36–50% depending on dose/analysis	GI events common; dose‑related; low discontinuation in GLORY‑1	People comparing GLP‑1 + glucagon strategy vs other incretin paths [2]
Semaglutide / Wegovy (GLP‑1 RA)	GLP‑1R	68 weeks	−14.9% vs −2.4% placebo in adult weight‑management studies summarized in labeling	GI events common; class warnings in labeling	Baseline comparator for “GLP‑1‑only” weight‑loss approach [25]
Tirzepatide / Zepbound (dual incretin)	GIPR + GLP‑1R	72 weeks	Up to −20.9% (15 mg) vs −3.1% placebo in Study 1 at week 72 (labeling); high responder rates at ≥15% and ≥20%	GI events common; label includes class warnings and additional safety notes	Benchmark for “GLP‑1 + GIP” maximal weight‑loss performance in an approved U.S. therapy [26]
Retatrutide (triple agonist, investigational)	GLP‑1R + GIPR + GCGR	48 weeks	Up to −24.2% (12 mg) vs −2.1% placebo at week 48 in phase 2	GI events common; heart rate increases noted; investigational	“Next‑gen” comparison for multi‑agonist ceiling (not the same evidence maturity as approvals) [27]

Key comparison takeaway: Percent weight loss is highly time‑dependent (48 vs 68 vs 72 weeks), so treat cross‑trial comparisons as directional—not definitive. [1]

Mazdutide vs semaglutide: what’s the cleanest, evidence‑safe statement?

Mazdutide vs semaglutide: Mazdutide is GLP‑1 + glucagon receptor agonism, while semaglutide is GLP‑1‑only, so the second receptor and related metabolic effects differ by design. Semaglutide has extensive global approval history and multiple labeled indications; mazdutide’s approvals and availability are more region‑specific and newer. [28]

Mazdutide vs tirzepatide: what are you really comparing?

Mazdutide vs tirzepatide: you’re comparing GLP‑1 + glucagon vs GLP‑1 + GIP. Both can deliver meaningful weight loss, but their “second receptor” is not interchangeable, and trial timeframes differ (GLORY‑1 reporting through week 48 vs Zepbound obesity studies reporting through week 72 in labeling). [29]

Templates / Checklist / Example

The Mazdutide “research literacy” checklist (copy‑ready)

Use this checklist to evaluate Mazdutide pages, vendor claims, and forum discussions with less confusion.

Define the mechanism as GLP‑1R + GCGR (not GLP‑1/GIP). [30]
Confirm where it’s approved and what “availability” actually means in your country. [13]
Anchor weight‑loss expectations to phase 3 results (week 48 outcomes, responder rates, discontinuations). [2]
Compare across trials only after matching weeks + population + endpoints (48 vs 68 vs 72). [1]
Expect GI effects to be common and dose‑related; treat “no side effects” claims as marketing. [21]
Separate primary outcomes (weight change) from secondary signals (waist, lipids, liver fat imaging). [22]
Remember weight regain after stopping can occur; don’t assume permanence from on‑treatment graphs. [22]

A simple “Two‑Lever” model for understanding Mazdutide (unique insight)

Many competing pages explain Mazdutide as “strong GLP‑1,” which misses the point. A clearer mental model is two levers:

Lever one: Intake (satiety/appetite). GLP‑1 signaling supports satiety and appetite reduction and can affect gastric emptying. [7]

Lever two: Output (metabolic effects via glucagon pathway). Glucagon signaling is linked to hepatic glucose production and lipid metabolism; dual agonism is explored to seek weight loss while managing glucagon’s hyperglycemic tendency through GLP‑1 counterbalance. [5]

This is the core theme: Mazdutide isn’t “just a GLP‑1”—it’s an engineered balance of appetite and metabolic signaling. [30]

A practical example: how to read GLORY‑1 in one minute

If you only look at three numbers, look at these:

Week 48 average loss: about −11% (4 mg) and −14% (6 mg) vs placebo. [20]
Responder reality: meaningful proportions achieved ≥10% and ≥15% thresholds, and these were much higher than placebo. [20]
Tolerability reality: nausea, diarrhea, vomiting are common; discontinuation due to adverse events was low in this trial. [31]

A quick note on “fatty liver” terminology you’ll see

You may see older terms like NAFLD/MAFLD and newer terms like MASLD and MASH. MASLD replaced NAFLD as part of a 2023 multisociety consensus, with liver societies publishing practical explanations and diagnostic framing for the new nomenclature. [32]

GLORY‑1 included participants with liver steatosis and reports that mazdutide “appeared” associated with greater reductions in liver‑fat content vs placebo in that subgroup analysis. [22]

FAQs

Is Mazdutide approved in the United States?

Is Mazdutide approved in the United States? Mazdutide is not presented as an FDA‑approved chronic weight‑management drug in U.S. labeling the way Wegovy (semaglutide) and Zepbound (tirzepatide) are. Those products have FDA approvals for chronic weight management with publicly available prescribing information, while Mazdutide’s approvals are described in other regions such as China. [33]

How much weight can people lose on Mazdutide in human trials?

How much weight can people lose on Mazdutide in human trials? In the GLORY‑1 phase 3 trial, average weight change at week 48 was about −11% (4 mg) and −14% (6 mg), with placebo near flat. In a phase 2 trial over 24 weeks, weight loss was dose‑dependent up to −11.3% (6 mg) vs placebo. [34]

What side effects are most common with Mazdutide?

What side effects are most common with Mazdutide? The most common Mazdutide side effects reported in GLORY‑1 were gastrointestinal—especially nausea, diarrhea, and vomiting—and they were usually mild to moderate. Rates increased with higher dose, and events clustered during dose escalation. Discontinuation due to adverse events was low in GLORY‑1. [21]

Is Mazdutide the same as semaglutide or Ozempic/Wegovy?

Is Mazdutide the same as semaglutide or Ozempic/Wegovy? Mazdutide is not the same as semaglutide because Mazdutide activates GLP‑1 and glucagon receptors, while semaglutide is GLP‑1‑only. Both are “GLP‑1‑era” therapies, but Mazdutide’s second receptor (glucagon) changes the intended metabolic profile and the comparison logic. [35]

Does Mazdutide improve blood sugar in type 2 diabetes?

Does Mazdutide improve blood sugar in type 2 diabetes? Mazdutide improved HbA1c and reduced body weight versus dulaglutide in a randomized phase 3 trial in type 2 diabetes over 28 weeks. In that study, both 4 mg and 6 mg doses showed superior HbA1c reductions and greater weight reduction compared with dulaglutide. [36]

Can Mazdutide help fatty liver (MASLD/MASH)?

Can Mazdutide help fatty liver (MASLD/MASH)? Mazdutide showed liver‑fat imaging improvements in a trial subgroup with steatosis, but that is not the same as proving long‑term clinical liver outcomes. The broader liver disease field has updated terminology to MASLD/MASH (replacing NAFLD/NASH) via multisociety consensus, so future studies may frame endpoints using that nomenclature. [37]

Next Steps

If you remember one thing: Mazdutide is a GLP‑1 + glucagon dual‑agonist with phase 3 evidence of ~11–14% average weight loss at 48 weeks, and GI tolerability is the main trade‑off signal. [2]

If you want to keep learning with a “peptide‑literate” lens: – Use the “Three‑Lens Trial Check” above for any drug claim you see. – Compare drugs only when the trial week and population match.

For readers of PeptideDosages.com[38] who specifically want protocol‑math and vial‑strength context (educational framing, not personal medical guidance), these internal resources are relevant: – Mazdutide 5 mg vial dosage protocol – Mazdutide 10 mg vial dosage protocol

If you’re exploring liver‑fat terminology and why you’ll increasingly see MASLD/MASH in newer studies, start with the liver society overview from American Association for the Study of Liver Diseases[39]. [40]

[1] [2] [3] [5] [6] [10] [12] [18] [19] [20] [21] [22] [23] [29] [31] [34] [37] [38] [39] Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight